Trials / Completed
CompletedNCT01891526
Single Dose of 9-cis-retinoic Acid in Hepatic Patients
The Pharmacokinetics of a Single Dose of 9-cis-retinoic Acid (Alitretinoin, Toctino®) in Patients With Moderate to Severe Hepatic Insufficiency
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (actual)
- Sponsor
- University Hospital, Gentofte, Copenhagen · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
To test whether patients with hepatic insufficiency can tolerate one oral dose of 9-cis-retinoic acid and to test whether the metabolism of retinoic acid is altered.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 9-cis-retinoic acid | Single dose of 9-cis-retinoic acid (Capsule 30 mg) as oral exposure |
Timeline
- Start date
- 2010-12-01
- Primary completion
- 2012-06-01
- Completion
- 2012-06-01
- First posted
- 2013-07-03
- Last updated
- 2013-07-03
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT01891526. Inclusion in this directory is not an endorsement.